OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
ACUT
Accustem Sciences Inc.
0.74
0.14
23.33%
0.70 / 0.81 (2000 x 2500)
Accustem Sciences Inc.
5 Penn Plaza
19th Floor
New York, NY 10001
420 Lexington Ave
Suite 1402
New York, NY 10170
Since April 2004, Mr. Brancaccio has been the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. Mr. Brancaccio served as a director of Callisto Pharmaceuticals, Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and has been a director of Tamir Biotechnology, Inc. (formerly Alfacell Corporation) since April 2004, as well as a director of Trovagene, Inc. since December 2005, Synergy Pharmaceuticals Inc. since July 2008 and ContraVir Pharmaceuticals, Inc. since December 2013.
None
India
12275 El Camino Real
Suite 200
San Diego, CA 92130
StemPrint is a proprietary 20-gene test that leverages the biology of stem cells to predict cancer recurrence risk. Based on published research, several of the 20 genes display a connection to metastatic dissemination through their role in matrix degradation, migration, invasion and engraftment.
The company currently does not lease any premises directly.
